Related references
Note: Only part of the references are listed.A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer
Hatem Soliman et al.
CLINICAL CANCER RESEARCH (2021)
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer
R. Connor Chick et al.
CLINICAL IMMUNOLOGY (2021)
STING agonist promotes CAR T cell trafficking and in breast cancer
Nuo Xu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Zhuting Hu et al.
NATURE MEDICINE (2021)
Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2021)
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer
Megumi Kai et al.
SCIENTIFIC REPORTS (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).
Kai Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.
Hatem Hussein Soliman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.
Amy Jo Chien et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Luis Teixeira et al.
CLINICAL CANCER RESEARCH (2020)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab et al.
CANCER DISCOVERY (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Immuno-oncology drug development forges on despite COVID-19
Samik Upadhaya et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)
Melinda L. Telli et al.
CANCER RESEARCH (2020)
Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer
Joel Randolph Hecht et al.
CANCER RESEARCH (2020)
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva et al.
LANCET ONCOLOGY (2019)
A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC).
Leonel Fernando Hernandez-Aya et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Vaccine Therapies for Breast Cancer
Erin E. Burke et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2019)
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging-A Literature Review
Gabrielle Planes-Laine et al.
CANCERS (2019)
Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1
Bridget Marcinkowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
Engineering dendritic cell vaccines to improve cancer immunotherapy
Caleb R. Perez et al.
NATURE COMMUNICATIONS (2019)
Engineered T Cell Therapy for Cancer in the Clinic
Lijun Zhao et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
If we build it they will come: targeting the immune response to breast cancer
Margaret E. Gatti-Mays et al.
NPJ BREAST CANCER (2019)
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Anna E. Vilgelm et al.
FRONTIERS IN IMMUNOLOGY (2019)
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
Ketil A. Camilio et al.
BREAST CANCER RESEARCH (2019)
A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
Prasad S. Adusumilli et al.
CANCER RESEARCH (2019)
Genetically engineered T cells for cancer immunotherapy
Dan Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe et al.
JCI INSIGHT (2019)
Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer
Lucy M. De La Cruz et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment
Marie-Nicole Theodoraki et al.
CANCER RESEARCH (2018)
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
Kimberly R. Kalli et al.
CLINICAL CANCER RESEARCH (2018)
A phase 1 study of p53MVA vaccine in combination with pembrolizumab.
Vincent M. Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Driving T-cell immunotherapy to solid tumors
Ken Garber
NATURE BIOTECHNOLOGY (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents
Natasa Obermajer et al.
NATURE PROTOCOLS (2018)
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2018)
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M. Conry et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
A phase I study of adoptive immunotherapy for advanced ROR1+malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)
Jennifer M. Specht et al.
CANCER RESEARCH (2018)
Oncolytic Virotherapy for Breast Cancer Treatment
Samia M. O'Bryan et al.
CURRENT GENE THERAPY (2018)
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Antoni Ribas et al.
CANCER DISCOVERY (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma A Nonrandomized Clinical Trial
Ajay K. Nooka et al.
JAMA ONCOLOGY (2018)
Harnessing immune checkpoints for cancer therapy
Dass S. Vinay et al.
IMMUNOTHERAPY (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
V. Bernstein et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Personalized cancer vaccines: Targeting the cancer mutanome
Xiuli Zhang et al.
VACCINE (2017)
Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
Laura F. Hutchins et al.
ONCOTARGET (2017)
Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
Xiuli Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
Yuan Yuan et al.
ONCOIMMUNOLOGY (2017)
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Marjorie G. Zauderer et al.
CLINICAL CANCER RESEARCH (2017)
LTX-315, an oncolytic peptide, to convert immunogenically 'cold' tumors to 'hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.
James F. Spicer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
Chantale Bernatchez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunotherapy for Breast Cancer: Current and Future Strategies
Austin D. Williams et al.
CURRENT SURGERY REPORTS (2017)
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
G. Pruneri et al.
ANNALS OF ONCOLOGY (2016)
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
Simona Bramante et al.
ONCOIMMUNOLOGY (2016)
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2016)
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
Megan C. Duggan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
The Role of Sialyl-Tn in Cancer
Jennifer Munkley
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
Lily Francis et al.
ONCOTARGET (2016)
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Lance D. Miller et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts).
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer
Claudia Paret et al.
ONCOTARGET (2015)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Christopher R. Heery et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer A Randomized Clinical Trial
Christopher R. Heery et al.
JAMA ONCOLOGY (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
Mesothelin expression is associated with poor outcomes in breast cancer
Yun R. Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Interleukin 12: still a promising candidate for tumor immunotherapy?
Witold Lasek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Michael D. Iglesia et al.
CLINICAL CANCER RESEARCH (2014)
Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival
Maha Ayyoub et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
Ryuji Takahashi et al.
BREAST CANCER RESEARCH (2014)
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
D. W. Kufe
ONCOGENE (2013)
Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial
Nuhad K. Ibrahim et al.
JOURNAL OF CANCER (2013)
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Julia Tchou et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
Chun-Jian Qi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
Vanja Sisirak et al.
CANCER RESEARCH (2012)
NF-κB Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells
Ravikumar Muthuswamy et al.
CANCER RESEARCH (2012)
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
Thomas Karn et al.
EUROPEAN JOURNAL OF CANCER (2012)
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
Neil L. Berinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth
Suping Zhang et al.
PLOS ONE (2012)
NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
Foluso O. Ademuyiwa et al.
PLOS ONE (2012)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohebtash et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Molecular Stratification of Triple-Negative Breast Cancers
Charles M. Perou
ONCOLOGIST (2011)
Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi et al.
CLINICAL CANCER RESEARCH (2010)
Immunogenicity and safety of a NeuGcGM3 based cancer vaccine Results from a controlled study in metastatic breast cancer patients
Vladimir Mulens et al.
HUMAN VACCINES (2010)
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
James L. Gulley et al.
CLINICAL CANCER RESEARCH (2008)
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
Tetsuhiro Tsuruma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Telomerase-specific T-Cell immunity in breast cancer: Effect of vaccination on tumor immunosurveillance
Susan M. Domchek et al.
CANCER RESEARCH (2007)
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
Inge Marie Svane et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes
RH Vonderheide et al.
CLINICAL CANCER RESEARCH (2004)
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
D Avigan et al.
CLINICAL CANCER RESEARCH (2004)
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine
A Carr et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial
T Gilewski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Anti-tumor immunity induced by Interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells
CM Divino et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Share Paper
